In this podcast, prof. dr. Egbert Smit explains the interim results of the DESTINY-Lung01 study. In this trial, patients with metastatic non-small cell lung cancer and a HER-mutation were treated with trastuzumab deruxtecan (T-DXd). Listen now to hear more about the results and implications of this study.
Top
